E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFA
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma
Trial Timeline
Oct 1, 2011 โ Jul 1, 2012
NCT ID
NCT01460511About E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFA
E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFA is a phase 3 stage product being developed by Amphastar Pharmaceuticals for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01460511. Target conditions include Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01460511 | Phase 3 | Completed |
Competing Products
20 competing products in Asthma
Other Products from Amphastar Pharmaceuticals
albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFAPhase 3
72
Placebo + Primatene Mist + Epinephrine inhalationPhase 3
72
Armstrong Albuterol Sulfate Inhalation Aerosol + Albuterol Sulfate Inhalation AerosolPhase 3
72
albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placeboPhase 3
72
Epinephrine HFA-MDI (E004) + Placebo-HFAPhase 3
72